UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Perspective Therapeutics, Inc. (NYSE:CATX) by 19.6% during the 4th quarter, Holdings Channel reports. The firm owned 70,150 shares of the company’s stock after buying an additional 11,472 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Perspective Therapeutics were worth $224,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new stake in Perspective Therapeutics during the 4th quarter valued at $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $34,000. National Bank of Canada FI increased its position in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC increased its position in Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in Perspective Therapeutics in the 4th quarter valued at about $51,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Trading Down 1.8%

Shares of CATX opened at $3.22 on Friday. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.55. The company’s fifty day moving average is $2.44 and its two-hundred day moving average is $2.87.

Insider Buying and Selling

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 38,145 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the transaction, the director now owns 108,982 shares in the company, valued at $233,221.48. This trade represents a 53.85% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Johan M. Spoor purchased 22,026 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The stock was acquired at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 115,696 shares of company stock valued at $256,344. 3.72% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CATX shares. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $12.63.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.